Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15308683 | 1.00 | HTR2A (0.69) | HTR2AIARS1 | |
| SCHEMBL31185688 | 1.00 | HTR2A (0.69) | HTR2AIARS1 | |
| SCHEMBL9043584 | 1.00 | HTR2A (0.69) | HTR2AIARS1 | |
| SCHEMBL11060862 | 0.89 | HTR2A (0.64) | HTR2AIARS1 | |
| SCHEMBL11104808 | 0.89 | HTR2A (0.64) | HTR2AIARS1 | |
| SCHEMBL11238117 | 0.88 | HTR2A (0.71) | HTR2AIARS1 | |
| SCHEMBL11067269 | 0.88 | HTR2A (0.71) | HTR2AIARS1 | |
| SCHEMBL11063564 | 0.86 | HTR2A (0.74) | HTR2AIARS1 | |
| SCHEMBL11098657 | 0.86 | HTR2A (0.60) | HTR2AIARS1 | |
| SCHEMBL9372908 | 0.86 | HTR2A (0.59) | HTR2AIARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616655-B2 | Topical antibiotic containing pharmaceutical composition for bacterial infections and wound healing | VISHAGAN VANANGAMUDI SULUR (IN) | 2026-05-05 | — | — | US | disclosed |
| CN-116761599-B | Deuterated or partially deuterated N, N-dimethyltryptamine compounds | 赛本英国有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025108865-A1 | HERBICIDAL COMPOSITIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-30 | — | — | WO | disclosed |
| CN-116440913-B | Modified hydrogenation catalyst and preparation method thereof | 中国石油化工股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-115651062-B | Derivatives of maleic acid, preparation method and application thereof | 首都医科大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-107846879-B | Adjuvant for agricultural chemicals | 罗曼·谢夫奇克 | 2024-04-23 | — | — | CN | disclosed |
| EP-3968956-B1 | A TOPICAL PHARMACEUTICAL MUPIROCIN COMPOSITION FOR BACTERIAL INFECTIONS AND WOUND HEALING | SULUR VISHAGAN VANANGAMUDI (IN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117158570-A | Stevia plant and application thereof | 谱赛科美国股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-4010339-B1 | HERBICIDAL AMIDES | BASF SE (DE) | 2023-09-06 | — | — | EP | disclosed |
| CN-110475484-B | Stevia plant and application thereof | 谱赛科美国股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-4256762-A | ESTERS OF MONIC ACID | BEECHAM GROUP LIMITED (GB) | 1981-03-17 | — | — | US | disclosed |
| US-4256879-A | BACTERICIDES, FURFURYLMETHYL, EPOXYPROPYL | BEECHAM GROUP LIMITED (GB) | 1981-03-17 | — | — | US | disclosed |
| US-4237161-A | BRONCHITIS AND VENERAL DISEASE | BEECHAM GROUP LIMITED (GB) | 1980-12-02 | — | — | US | disclosed |
| US-4235784-A | Antibacterial compounds | BEECHAM GROUP LIMITED (GB) | 1980-11-25 | — | — | US | disclosed |
| US-4217448-A | MONIC ACID DERIVATIVES | BEECHAM GROUP LIMITED (GB) | 1980-08-12 | — | — | US | disclosed |
| US-4217447-A | Antibacterial compounds | BEECHAM GROUP LIMITED (GB) | 1980-08-12 | — | — | US | disclosed |
| US-4166863-A | ACTIVE AGAINST HEMOPHILUS AND NEISSERIA | BEECHAM GROUP LIMITED (GB) | 1979-09-04 | — | — | US | disclosed |
| US-4152337-A | KETONES | BEECHAM GROUP LIMITED (GB) | 1979-05-01 | — | — | US | disclosed |
| US-4102904-A | MONIC ACID | BEECHAM GROUP LIMITED (GB) | 1978-07-25 | — | — | US | disclosed |
| US-4102901-A | MONIC ACID ESTERS | BEECHAM GROUP LIMITED (GB) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616655-B2 | Topical antibiotic containing pharmaceutical composition for bacterial infections and wound healing | COL1A1, COL14A1, COL2A1 | HTR2A 3899/4885IARS1 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.